US2023107561A1PendingUtilityA1

Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant

77
Assignee: SELECTA BIOSCIENCES INCPriority: Mar 11, 2017Filed: Aug 30, 2022Published: Apr 6, 2023
Est. expiryMar 11, 2037(~10.6 yrs left)· nominal 20-yr term from priority
Inventors:Lloyd Johnston
A61K 45/06C12Y 107/03003A61K 31/573A61K 31/445A61K 31/436A61K 31/165A61K 31/192A61K 9/5153A61K 9/51A61K 2300/00A61P 19/06A61K 38/44A61P 29/00A61K 38/43A61K 45/00A61P 37/06
77
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein are methods and compositions, such as kits, related to compositions comprising synthetic nanocarriers comprising an immunosuppressant and compositions comprising an uricase and a composition comprising an anti-inflammatory therapeutic. Also provided herein are methods and compositions for the treatment of subjects in need of administration or treatment with the uricase.

Claims

exact text as granted — not AI-modified
1 . A method, comprising:
 concomitantly administering to a subject in need thereof 1) a composition comprising synthetic nanocarriers comprising an immunosuppressant and 2) a composition comprising an uricase; and further comprising administering 3) a composition comprising an anti-inflammatory therapeutic, wherein the composition comprising an anti-inflammatory therapeutic is administered concomitantly with the composition comprising synthetic nanocarriers comprising an immunosuppressant and the composition comprising an uricase.   
     
     
         2 . The method of  claim 1 , wherein the composition comprising an anti-inflammatory therapeutic is administered prior to the composition comprising synthetic nanocarriers comprising an immunosuppressant and the composition comprising an uricase. 
     
     
         3 . The method of  claim 1 , wherein the anti-inflammatory therapeutic is administered at least once prior. 
     
     
         4 . The method of  claim 1 , wherein the anti-inflammatory therapeutic is administered a week prior. 
     
     
         5 . The method of  claim 1 , wherein the anti-inflammatory therapeutic is a NSAID. 
     
     
         6 . The method of  claim 1 , wherein the anti-inflammatory therapeutic is colchicine or ibuprofen. 
     
     
         7 . The method of  claim 1 , wherein the method further comprises administering to the subject one or more compositions comprising an infusion reaction therapeutic. 
     
     
         8 . The method of  claim 7 , wherein the one or more compositions comprising an infusion reaction therapeutic comprises an antihistamine and/or a corticosteroid. 
     
     
         9 . The method of  claim 8 , wherein the antihistamine is fexofenadine. 
     
     
         10 . The method of  claim 8 , wherein the corticosteroid is methylprednisolone, prednisone or dexamethasone. 
     
     
         11 . The method of  claim 7 , wherein the one or more compositions comprising an infusion reaction therapeutic is/are administered at least once prior to the composition comprising synthetic nanocarriers comprising an immunosuppressant and the composition comprising an uricase. 
     
     
         12 . The method of  claim 11 , wherein the composition(s) comprising an infusion reaction therapeutic is administered at least twice prior to the composition comprising synthetic nanocarriers comprising an immunosuppressant and the composition comprising an uricase. 
     
     
         13 . The method of  claim 7 , wherein the composition(s) comprising an infusion reaction therapeutic is administered within 24 hours of the composition comprising synthetic nanocarriers comprising an immunosuppressant and the composition comprising an uricase. 
     
     
         14 . The method of  claim 1 , wherein the uricase is pegylated uricase. 
     
     
         15 . The method of  claim 14 , wherein the pegylated uricase is pegadricase or pegloticase. 
     
     
         16 . The method of  claim 1 , wherein the immunosuppressant is an mTOR inhibitor. 
     
     
         17 . The method of  claim 16 , wherein the mTOR inhibitor is a rapalog. 
     
     
         18 . The method of  claim 17 , wherein the rapalog is rapamycin. 
     
     
         19 . The method of  claim 1 , wherein the subject is human. 
     
     
         20 - 49 . (canceled) 
     
     
         50 . A composition, comprising:
 1) a composition comprising synthetic nanocarriers comprising an immunosuppressant and   2) a composition comprising an uricase; and further comprising administering 3) a composition comprising an anti-inflammatory therapeutic.   
     
     
         51 - 83 . (canceled)

Join the waitlist — get patent alerts

Track US2023107561A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.